Please select the option that best describes you:

Topics: Interstitial lung disease • Pulmonology • ACR Journal Club • Diffuse Parenchymal Lung Disease

Do you use combination therapy with nintedanib and nerandomilast in patients with idiopathic pulmonary fibrosis (IPF) who have been clinically stable on nintedanib for more than six months?